147 related articles for article (PubMed ID: 31449053)
21. The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation.
Chung C; Yoo G; Kim T; Lee D; Lee CS; Cha HR; Park YH; Moon JY; Jung SS; Kim JO; Lee JC; Kim SY; Park HS; Park M; Park DI; Lim DS; Jang KW; Lee JE
Biochem Biophys Res Commun; 2016 Oct; 479(2):152-158. PubMed ID: 27475501
[TBL] [Abstract][Full Text] [Related]
22. Pulling a MAST1 on Cisplatin Resistance.
Jaykumar AB; Karra AS; Cobb MH
Cancer Cell; 2018 Aug; 34(2):183-185. PubMed ID: 30107173
[TBL] [Abstract][Full Text] [Related]
23. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
Tian J; Lin Y; Yu J
Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
[TBL] [Abstract][Full Text] [Related]
24. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
25. Stabilization of integrin-linked kinase by binding to Hsp90.
Aoyagi Y; Fujita N; Tsuruo T
Biochem Biophys Res Commun; 2005 Jun; 331(4):1061-8. PubMed ID: 15882985
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of RIP3 potentiates cisplatin chemoresistance by triggering HSP90-ERK pathway mediated DNA repair in esophageal squamous cell carcinoma.
Sun Y; Zhai L; Ma S; Zhang C; Zhao L; Li N; Xu Y; Zhang T; Guo Z; Zhang H; Xu P; Zhao X
Cancer Lett; 2018 Apr; 418():97-108. PubMed ID: 29331417
[TBL] [Abstract][Full Text] [Related]
27. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of HIPK2 by escape from proteasomal degradation mediated by the E3 ubiquitin ligase Siah1.
Kim SY; Choi DW; Kim EA; Choi CY
Cancer Lett; 2009 Jul; 279(2):177-84. PubMed ID: 19250734
[TBL] [Abstract][Full Text] [Related]
31. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
32. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
33. The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.
Zhang HT; Zeng LF; He QY; Tao WA; Zha ZG; Hu CD
Biochim Biophys Acta; 2016 Feb; 1863(2):335-46. PubMed ID: 26658161
[TBL] [Abstract][Full Text] [Related]
34. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
35. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
[TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
37. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
[TBL] [Abstract][Full Text] [Related]
38. Hsp90 regulates activation of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-infected cells.
Yang K; Shi H; Qi R; Sun S; Tang Y; Zhang B; Wang C
Mol Biol Cell; 2006 Mar; 17(3):1461-71. PubMed ID: 16394098
[TBL] [Abstract][Full Text] [Related]
39. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
[TBL] [Abstract][Full Text] [Related]
40. Silencing of the SNARE protein NAPA sensitizes cancer cells to cisplatin by inducing ERK1/2 signaling, synoviolin ubiquitination and p53 accumulation.
Wu ZZ; Sun NK; Chien KY; Chao CC
Biochem Pharmacol; 2011 Dec; 82(11):1630-40. PubMed ID: 21903092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
